CONTROLLED RELEASE – Informed Selection of Modified-Release Technologies Provides Simpler Oral Dose Regimens
Ronak Savla, PhD, reviews some of the physicochemical and biopharmaceutical characteristics of drugs and how they influence creation of a controlled drug delivery formulation.
Lev Gerlovin and Pascale Diesel, PharmD, believe there is significant evidence to indicate that we are entering a golden age of gene and cell therapy development, and while industry works to advance these programs, the debate over new approaches in both structuring and financing clinical research is likely to continue.
LIPID-BASED DELIVERY – Advanced Lipid-Based Drug Delivery Systems: Solid Lipid Nanoparticles & Nanostructured Lipid Carriers
John K. Tillotson, RPh, PhD, believes increased research and development of these drug delivery platforms will continue to advance therapeutic efficacy and safety for emerging difficult-to-deliver actives.
DRUG DELIVERY – Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
Marc A. Iacobucci says that with much attention and research investment into IOT, NanOlogy is shaping a new paradigm for cancer treatment by attempting to improve the safety and effectiveness of tried and true CT through local delivery.
GLOBAL REPORT – 2017 Global Drug Delivery & Formulation Report: Part 4, The Drug Delivery & Formulation Pipeline
In the final installment of this 4-part series, PharmaCircle in collaboration with Drug Development & Delivery, provides a pipeline review and analysis (centered on drug delivery and formulation products) looking forward and back 5 years for a total of 10 years.
David S. Johnson, PhD, provides a unique insight into immune dysregulation through a proprietary technology known as Surge – a platform that quickly characterizes every cell in complex immune systems so that natural immune repertoires can be translated into medical treatments.
Joel Tune, MBA, says for those peptide therapeutics that meet the necessary criteria, advances in formulation technologies coupled with favorable market dynamics will continue to drive interest across the entire prescription drug spectrum for safe and effective orally administered peptide therapeutics.
Richard Gray, MA, and Pavel Abdulkin, PhD, look at how microfluidics is changing the drug development sector and explore an exciting new non-encapsulating microparticle-based approach that offers “tunable” release of the API.
PERSONALIZED IMMUNOTHERAPY – Off-the-Shelf Personalized Immunotherapy for Breast Cancer: The BriaCell Solution
William V. Williams, MD, Markus Lacher, PhD, and Charles L. Wiseman, MD, explain how there is a clear need for ways to stimulate effective cancer-specific immune responses while avoiding time-consuming and costly individualized manufacturing.
Jaspreet Arora, PhD, Samantha Saville, and Brett Waybrant, PhD, focus on a controlled-release LMP formulation to identify optimum annealing conditions and to better understand the annealing mechanism.
EXCLUSIVE ONLINE CONTENT
West recently announced it has commenced discussions with two companies regarding the use of West’s proprietary SmartDose drug delivery platform for complex molecules.
The EMA’s human medicines committee (CHMP) has recommended for the first time an adjunct treatment to insulin in the form of a tablet for certain patients with type 1 diabetes mellitus.
Q BioMed Inc., a biotechnology acceleration company, recently announced its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada.
Pharmapack Report Predicts Diversification of Innovation Leading to a Rise in Licensing & Partnering
Pharmapack Europe (February 6-7, Paris Expo Porte de Versailles, Paris) has released a European Drug Delivery and Packaging report, ahead of the event’s opening, which highlights, major challenges and opportunities for the industry in the year ahead.
MedPharm Ltd recently announced the expansion of its US Center of Excellence in Durham, NC, in response to increasing service demand for its topical and transdermal formulation development and performance testing services.